165 related articles for article (PubMed ID: 31838077)
1. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
Hamzic S; Kummer D; Froehlich TK; Joerger M; Aebi S; Palles C; Thomlinson I; Meulendijks D; Schellens JHM; García-González X; López-Fernández LA; Amstutz U; Largiadèr CR
Pharmacol Res; 2020 Feb; 152():104594. PubMed ID: 31838077
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
[TBL] [Abstract][Full Text] [Related]
3. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer.
Castro-Rojas CA; Esparza-Mota AR; Hernandez-Cabrera F; Romero-Diaz VJ; Gonzalez-Guerrero JF; Maldonado-Garza H; Garcia-Gonzalez IS; Buenaventura-Cisneros S; Sanchez-Lopez JY; Ortiz-Lopez R; Camacho-Morales A; Barboza-Quintana O; Rojas-Martinez A
Drug Metab Pers Ther; 2017 Dec; 32(4):209-218. PubMed ID: 29257755
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of fluorouracil -based chemotherapy toxicity.
Matsusaka S; Lenz HJ
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):811-21. PubMed ID: 25800061
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele.
Meulendijks D; Jacobs BA; Aliev A; Pluim D; van Werkhoven E; Deenen MJ; Beijnen JH; Cats A; Schellens JH
Int J Cancer; 2016 Jan; 138(1):245-53. PubMed ID: 26189437
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
11. Gender-dependent association of
Ioannou C; Ragia G; Balgkouranidou I; Xenidis N; Amarantidis K; Koukaki T; Biziota E; Kakolyris S; Manolopoulos VG
Pharmacogenomics; 2021 Jul; 22(11):669-680. PubMed ID: 34100299
[No Abstract] [Full Text] [Related]
12. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
13. TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Chao YL; Anders CK
Clin Breast Cancer; 2018 Jun; 18(3):e301-e304. PubMed ID: 28899623
[No Abstract] [Full Text] [Related]
14. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.
García-González X; Cortejoso L; García MI; García-Alfonso P; Robles L; Grávalos C; González-Haba E; Marta P; Sanjurjo M; López-Fernández LA
Oncotarget; 2015 Mar; 6(8):6422-30. PubMed ID: 25691056
[TBL] [Abstract][Full Text] [Related]
15. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
16. Distribution of the most common polymorphisms in TYMS gene in Slavic population of central Europe.
Pastorakova A; Chandogova D; Chandoga J; Luha J; Bohmer D; Malova J; Braxatorisova T; Juhosova M; Reznakova S; Petrovic R
Neoplasma; 2017; 64(6):962-970. PubMed ID: 28895423
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
de With M; van Doorn L; Maasland DC; Mulder TAM; Oomen-de Hoop E; Mostert B; Homs MYV; El Bouazzaoui S; Mathijssen RHJ; van Schaik RHN; Bins S
Biomed Pharmacother; 2023 Mar; 159():114232. PubMed ID: 36630849
[TBL] [Abstract][Full Text] [Related]
18. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.
Kelemen LE; Earp M; Fridley BL; Chenevix-Trench G; ; Fasching PA; Beckmann MW; Ekici AB; Hein A; Lambrechts D; Lambrechts S; Van Nieuwenhuysen E; Vergote I; Rossing MA; Doherty JA; Chang-Claude J; Behrens S; Moysich KB; Cannioto R; Lele S; Odunsi K; Goodman MT; Shvetsov YB; Thompson PJ; Wilkens LR; Dörk T; Antonenkova N; Bogdanova N; Hillemanns P; Runnebaum IB; du Bois A; Harter P; Heitz F; Schwaab I; Butzow R; Pelttari LM; Nevanlinna H; Modugno F; Edwards RP; Kelley JL; Ness RB; Karlan BY; Lester J; Orsulic S; Walsh C; Kjaer SK; Jensen A; Cunningham JM; Vierkant RA; Giles GG; Bruinsma F; Southey MC; Hildebrandt MAT; Liang D; Lu K; Wu X; Sellers TA; Levine DA; Schildkraut JM; Iversen ES; Terry KL; Cramer DW; Tworoger SS; Poole EM; Bandera EV; Olson SH; Orlow I; Vestrheim Thomsen LC; Bjorge L; Krakstad C; Tangen IL; Kiemeney LA; Aben KKH; Massuger LFAG; van Altena AM; Pejovic T; Bean Y; Kellar M; Cook LS; Le ND; Brooks-Wilson A; Gronwald J; Cybulski C; Jakubowska A; Lubiński J; Wentzensen N; Brinton LA; Lissowska J; Hogdall E; Engelholm SA; Hogdall C; Lundvall L; Nedergaard L; Pharoah PDP; Dicks E; Song H; Tyrer JP; McNeish I; Siddiqui N; Carty K; Glasspool R; Paul J; Campbell IG; Eccles D; Whittemore AS; McGuire V; Rothstein JH; Sieh W; Narod SA; Phelan CM; McLaughlin JR; Risch HA; Anton-Culver H; Ziogas A; Menon U; Gayther SA; Gentry-Maharaj A; Ramus SJ; Wu AH; Pearce CL; Lee AW; Pike MC; Kupryjanczyk J; Podgorska A; Plisiecka-Halasa J; Sawicki W; Goode EL; Berchuck A;
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30134598
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase pharmacogenetics.
Marsh S
Invest New Drugs; 2005 Dec; 23(6):533-7. PubMed ID: 16267625
[TBL] [Abstract][Full Text] [Related]
20. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
